drugset

drugset / Trial / NCT01862003

Phase I/II Trial of Antagonism of HER in GI Cancer

NCT01862003 ↗

Phase 2 Completed 24 enrolled University College, London AstraZeneca · collab Cancer Research UK · collab National Institute for Health Research, United Kingdom · collab

NaSingle-groupOpen-labelTreatment

Summary

Recruitment to phase I of the PANTHER trial is complete. Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.

Timeline

Start: 2014-05
Primary completion: 2019-08-02
Completion: 2019-08-02

Publications

Propper DJ, Gao F, Saunders MP, Sarker D, Hartley JA, Spanswick VJ, Lowe HL, Hackett LD, Ng TT, Barber PR, Weitsman GE, Pearce S, White L, Lopes A, Forsyth S, Hochhauser D. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. Br J Cancer. 2023 Jan;128(2):245-254. doi: 10.1038/s41416-022-02015-x. Epub 2022 Nov 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAPITINIB	Small molecule	160 mg	—
Background	Irinotecan	Small molecule	180 mg/m2	Intravenous
Background	Leucovorin	Small molecule	350 mg	Intravenous
Background	fluorouracil	Small molecule	2400 mg/m2	Intravenous

Indications